Indication intelligence, analysis and sector perception

Regenerative Medicine Earnings Scorecard - Q4/18 - to date

February 11, 2019

Q4/18 financial results is a scorecard of  (AKA) earnings of 45 covered  companies 3 out of 45 ... The current LPS (loss per share) or net income, cash positions i.e. "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status" Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.  

RegMed Investors’ (RMi) mid-day: market forces aren’t the only factor snookering the sector

January 23, 2019

The opening was about the “feeling” of the oversold but, the reliance of trust versus conviction pushes the session … The Advance/Decline Line has deteriorated ... Yet the “bottoms” are being bought! There’s a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules. After gains, there’s pain; followed by advances, declines and other progressions or was it regressions?   Confidence perceived is not always value achieved!

RegMed Investors’ (RMi) mid-day: Editas Medicine (EDIT) CEO Resigns — collapsing gene editing peer group

January 22, 2019

EDIT (-$4.48 or -17.13%), Intellia Therapeutics (NTLA -$1.05 or -6.88%) and CRISPR Therapeutics (CRSP -$4.07 or -10.96%) equities plunged    EDIT volume is HIGH with 3.7 M shares traded <3 month average = 792.8 K shares, CRSP volume is also HIGH with 1.79 M shares traded <3 month average = 834.7 K shares> and NTLA volume is as LOWER with 577.05 K shares traded <3 month average = 694.3 K shares>